- ￥620 - 2200
- 善本生物
- 2693
- 2025年12月31日
- Western Blotting (WB), Flow Cytometry (FCM), Immunocytochemistry (IC)
- 兔
- Human, Mouse, Rat
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 浓度：
Recommended Dilutions：Western Blotting (WB): 1:1,000-1:5,000 Flow Cytometry (FCM): 1:2,000 Immunocytochemistry (IC): 1:100-1:1,000
- 应用范围：
Western Blotting (WB), Flow Cytometry (FCM), Immunocytochemistry (IC)
- 宿主：
兔
- 适应物种：
Human, Mouse, Rat
- 保质期：
One year
- 克隆性：
Rabbit mAb
- 保存条件：
Store at -20 °C for one year. Supplied in PBS (pH 7.4) containing 50% glycerol, and 0.02% sodium azide.
- 形态：
液体
- 亚型：
Rabbit IgG
- 免疫原：
A synthesized peptide derived from human TRAF6
- 规格：
20ul/50ul/100ul
| 规格： | 20ul | 产品价格： | ￥620.0 |
|---|---|---|---|
| 规格： | 50ul | 产品价格： | ￥1200.0 |
| 规格： | 100ul | 产品价格： | ￥2200.0 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
Tumor necrosis factor-α (TNF-α) is a cytokine (CK) that possesses a wide variety of biological activities, including potent antitumor activities (1 ) and immunomodulatory properties mediated through its binding to two TNF receptors (p55
PriCells: Primary cells culture with supplement of vascular endothelial growth factor (VEGF)
, move, or further differentiate. Hence, VEGF is a potential target for the treatment of cancer. The first anti-VEGF drug, a monoclonal antibody named bevacizumab, was approved in 2004. Approximately 10-15% of patients benefit from bevacizumab therapy; however, biomarkers
技术资料暂无技术资料 索取技术资料
